Synonym name: 4-Allyl-2-methoxyphenol; 5-Allylguaiacol
Catalogue No.: BP0569
Cas No.: 97-53-0
Formula: C₁₀H₁₂O₂
Mol Weight: 164.204
Botanical Source: Very widespread occurrence in essential oils. Major component of clove oil Eugenia caryophyllata (up to 95% of content of clove leaf oil). First clove oil in 1826. Also found in those of Cinnamomum spp., Cistus spp., Camellia spp., Pelargonium

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.

HPLC of Eugenol

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Eugenol (CAS No.: 97-53-0), an important natural compound, is mainly found in the essential oil of Syzygium aromaticum and is its primary active ingredient. Since ancient times, eugenol has been widely used in traditional medicine, especially dentistry, due to its remarkable antibacterial, analgesic, and antioxidant properties. In recent years, with the development of natural product pharmacology, the multibioactive properties and molecular mechanisms of eugenol have been deeply studied, demonstrating its potential value in the prevention and treatment of various diseases such as oral infections, inflammation, and tumors. This paper aims to systematically review the chemical structure and physicochemical properties of eugenol, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and its clinical application prospects, aiming to provide a theoretical basis and research direction for the development of natural product drugs.

Chemical structure and physicochemical properties

Eugenol is a typical phenylpropanoid compound with the chemical formula C10H12O2 and a molecular weight of 164.2040. Its structural feature is that on the guaiacol (4-hydroxybenzyl alcohol) framework, the hydroxyl parasite is replaced by an allyl chain, specifically forming 4-allyl-2-methoxyphenol. This structure gives eugenol its unique chemical and biological activity.

In terms of physicochemical properties, eugenol exhibits moderate lipid solubility, with a LogP value of about 2.4613, indicating good cell membrane penetration capability. The polar surface area (TPSA) was 29.46 Ų, indicating that its molecular polarity is relatively low, which is beneficial for blood-brain barrier penetration. Experimental data also indicate it has a high penetration capacity for the blood-brain barrier. Its low water solubility (0.8696) limits its solubility in the aqueous phase, but its volatility and oil solubility make it suitable for preparing volatile oil drugs. In terms of safety, eugenol did not show hERG channel inhibitory activity; the Ames test result was 0.6, indicating low mutagenicity and a solid safety foundation.

Plant Origins and Extraction Methods

Eugenol is mainly found in the flower buds, leaves, and branches of lilac plants, with dried lilac buds containing the highest content, accounting for about 70%-90% of the total essential oil. Clove plants are widely distributed in tropical and subtropical regions, with India, Indonesia, and Madagascar being especially abundant in clove production.

Traditional methods for extracting eugenol mainly include steam distillation and solvent extraction. Steam distillation is easy to operate and low-cost, and is commonly used for industrial-scale extraction of clove essential oil, but it easily leads to the degradation of some heat-sensitive components. Solvent extraction methods (such as organic solvents such as ethanol and ethyl acetate) can better preserve eugenol's active components, but there is a risk of solvent residue. In recent years, supercritical CO2 extraction technology has gradually become a research hotspot for eugenol extraction due to its green and environmentally friendly nature, strong selectivity, and absence of solvent residues. In addition, microwave-assisted extraction and ultrasound-assisted extraction technologies have also been developed to improve extraction efficiency and purity.

After extraction, eugenol is usually separated, purified, and content determined using chromatographic techniques (such as GC-MS for gas chromatography-mass spectrometry and HPLC) to ensure its medicinal quality.

Pharmacological activity research

Eugenol has broad and diverse pharmacological activities, covering antibacterial, anti-inflammatory, analgesic, antioxidant, antitumor, and parasitic aspects.

Antibacterial activity

Eugenol exhibits significant inhibitory effects on various Gram-positive and Gram-negative bacteria, especially against oral pathogens such as Streptococcus mutans, Staphylococcus aureus, and Porphyromonas gingivalis. Its main mechanism of action involves damaging the integrity of bacterial cell membranes, interfering with cellular metabolism and protein synthesis, thereby leading to bacterial death. Eugenol can also inhibit the formation of bacterial biofilms, reducing bacterial resistance and pathogenicity.

Anti-inflammatory and analgesic effects

Eugenol exerts anti-inflammatory effects by inhibiting the production and release of inflammatory mediators. Research shows that eugenol can downregulate the expression of cyclooxygenase-2 (COX-2, PTGS2), reducing the synthesis of prostaglandin E2 (PGE2), thereby alleviating inflammatory responses. Its analgesic effect is closely related to inhibiting the release of neurotransmitters and blocking pain transmission pathways, and is widely used clinically as an adjunct treatment for toothache and pulpitis.

Antioxidant activity

Eugenol has a strong free radical scavenging ability, effectively inhibiting lipid peroxidation and protecting cells from oxidative damage. Its antioxidant mechanisms include direct capture of reactive oxygen species (ROS), regulation of endogenous antioxidant enzyme activity (such as superoxide dismutase (SOD), glutathione peroxidase (GPx), and inhibition of oxidative stress-related signaling pathways.

Antitumor effects

In recent years, eugenol has demonstrated potential in various tumor models to inhibit tumor cell proliferation, induce apoptosis, and suppress metastasis. Its antitumor mechanism involves regulating cyclins, activating mitochondrial apoptosis pathways, inhibiting NF-κB signaling pathways, and modulating the inflammatory microenvironment, demonstrating promising application as adjunct anticancer drugs.

Other activities

Eugenol also exhibits various biological activities such as deworming, antiviral, and immunomodulatory, enriching its pharmacological value.

Mechanism of action and molecular targets

The multi-target mechanism of eugenol forms the basis of its broad pharmacological activity. For oral infection-related diseases, eugenol mainly targets the following key points:

• PTGS2 (COX-2): Eugenol inhibits PTGS2 expression, reduces the production of inflammatory mediator prostaglandins, and relieves inflammation and pain.
• NFKB1 (nuclear factor κB): By inhibiting the NF-κB signaling pathway, eugenol reduces the expression of inflammatory factors (such as TNF-α, IL-1β), alleviating inflammatory responses.
• ICAM1 (Intercellular Adhesion Molecule 1): Eugenol regulates ICAM1, reducing the migration of inflammatory cells to infected sites and alleviating tissue damage.
• GYRA (DNA Gyrase A) and FABI (Acyl Carrier Protein Synthase): As key enzymes for bacterial DNA replication and fatty acid synthesis, eugenol blocks bacterial proliferation by inhibiting these targets.
• DHFR (dihydrofolate reductase): eugenol inhibits bacterial DHFR and interferes with bacterial nucleic acid synthesis.
• GRPR (gastric release peptide receptor): involved in pain conduction, eugenol may mediate analgesic effects by modulating GRPR.

In addition, eugenol's antioxidant effects are also related to its regulation of intracellular redox balance, involving multiple signaling pathways such as Nrf2/ARE.

Druggability evaluation and pharmacokinetics

Eugenol possesses excellent druggability parameters. Its molecular weight is moderate, with moderate lipid solubility and polarity, which facilitates the absorption and distribution of the drug in the body. The high blood-brain barrier permeability gives it great potential for applications in central nervous system diseases. Low mutagenicity and absence of hERG inhibitory effects suggest good safety.

Pharmacokinetic studies show that eugenol is rapidly absorbed orally, with rapid plasma concentration peaks and widespread distribution in the body. It is mainly metabolized by the liver, with metabolites primarily excreted in urine. Its half-life is moderate, making it suitable for multiple doses to maintain efficacy. Its volatile and lipophilic characteristics make it excellent for topical administration, such as local oral applications.

However, eugenol has relatively low water solubility, limiting its oral bioavailability, so its efficacy and stability need to be enhanced through formulation optimization (such as nanocarriers, liposomes, etc.).

Prospects and outlooks for clinical applications

Eugenol, as a traditional natural medicinal ingredient, has a long history of use in oral medicine, especially in the adjunctive treatment of toothaches, pulpitis, and oral infections. Modern research further confirms its multiple mechanisms of antibacterial, anti-inflammatory, and analgesic effects, providing scientific evidence for its clinical promotion.

In the future, the clinical applications of eugenol can be expanded to:

• Comprehensive oral infection treatment: Combining modern formulation technology, developing efficient, low-irritation oral care products such as mouthwash, toothpaste, and topical patches.
• Antitumor adjuvant therapy: Based on its antitumor activity, eugenol is expected to become an adjunct drug in tumor treatment, especially in the treatment of localized tumors such as oral cancer.
• Neuroprotection and Analgesia: Its excellent blood-brain barrier permeability gives it potential for analgesic relief and protection in neurological diseases.
• Antioxidant and anti-inflammatory diseases: Can be developed for the prevention and treatment of chronic inflammation and oxidative stress-related diseases.

Moreover, the safety and multi-target mechanism of eugenol make it an important candidate for natural drug development. However, clinical promotion still requires addressing technical bottlenecks such as poor water solubility, low bioavailability, and dosage form stability. In the future, pharmacokinetic research on eugenol should be strengthened, administration routes optimized, and more clinical trials conducted to verify efficacy and safety.

Conclusion

Eugenol, as a widely sourced, simple structure, and biologically rich natural product, exhibits significant antibacterial, anti-inflammatory, analgesic, and antioxidant effects. Its mechanism of action involves multiple molecular targets, making it especially valuable in the prevention and treatment of oral infections and related diseases. Druggability evaluation shows eugenol has promising potential for drug development, but limitations such as water solubility and bioavailability still need to be overcome. In the future, through modern drug formulation technologies and systematic clinical research, eugenol is expected to become a model in the development of natural product drugs, providing new ideas and strategies for the treatment of oral and other related conditions.